TapewireFind a company

person · Reporting owner

FEDERMAN IRWIN

Disclosed activity across 7 companies

Tapewire entity
89572
SEC CIK
0001192391

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
GRID DYNAMICS HOLDINGS, INC.CTAC.U · Entity 2031DirectorOctober 04, 2018October 04, 2018
Inari Medical, Inc.NARI · Entity 8303510% ownerNovember 17, 2020November 20, 2020
ON24 INC.ONTF · Entity 11630DirectorJune 21, 2024June 25, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GRID DYNAMICS HOLDINGS, INC.

Report date October 04, 2018 · Filed October 04, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00IndirectSee FootnoteNot disclosed Reported balance Holding disclosure · report date 2018-10-04 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: Mr. Federman does not beneficially own any shares of the common stock of the issuer. However, Mr. Federman has a pecuniary interest in shares of Class B common stock through his ownership of membership interests of ChaSerg Technology Sponsor LLC (the "Sponsor"). As described in the issuer's registration statement on Form S-1 (File No. 333-227300) under the heading "Description of Securities--Founder Shares and Placement Shares", the shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and has no expiration date. Mr. Federman disclaims beneficial ownership over any securities owned by the Sponsor in which he does not have any pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Mr. Federman does not beneficially own any shares of the common stock of the issuer. However, Mr. Federman has a pecuniary interest in shares of Class B common stock through his ownership of membership interests of ChaSerg Technology Sponsor LLC (the "Sponsor"). As described in the issuer's registration statement on Form S-1 (File No. 333-227300) under the heading "Description of Securities--Founder Shares and Placement Shares", the shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and has no expiration date. Mr. Federman disclaims beneficial ownership over any securities owned by the Sponsor in which he does not have any pecuniary interest.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectDirectly owned by USVP X5,239,744 Reported balance After 2020-11-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2020-11-17 · Other · Disposed 2,245,605 · Balance 5,239,744

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP") and USVP X Affiliates Fund , L.P. ("AFF X" and, together with USVP X, the "USVP Funds", and may be deemed to have sole voting and dispositive power over the securities held by the USVP Funds. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by AFF X167,627 Reported balance After 2020-11-17 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2020-11-17 · Other · Disposed 71,840 · Balance 167,627

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP") and USVP X Affiliates Fund , L.P. ("AFF X" and, together with USVP X, the "USVP Funds", and may be deemed to have sole voting and dispositive power over the securities held by the USVP Funds. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by PMG X587,851 Reported balance After 2020-11-17 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2020-11-17 · Other · Acquired 587,851 · Balance 587,851

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F3: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by PMG X, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by PMG X0 Reported balance After 2020-11-17 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2020-11-17 · Other · Disposed 587,851 · Balance 0

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F4: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by PMG X, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by Federman37,268 Reported balance After 2020-11-17 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2020-11-17 · Other · Acquired 37,268 · Balance 37,268

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by Lewis60,883 Reported balance After 2020-11-17 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 6 · 2020-11-17 · Other · Acquired 60,883 · Balance 60,883

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by Lewis40,883 Reported balance After 2020-11-18 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 7 · 2020-11-18 · Sale · Disposed 20,000 · Balance 40,883

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.52 to $67.32, inclusive for sales on 11/18/2020. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Common StockSEC Table I · non-derivativeIndirectDirectly held by family trust controlled by Matteucci56,173 Reported balance After 2020-11-17 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 8 · 2020-11-17 · Other · Acquired 56,173 · Balance 56,173

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by Tansey67,730 Reported balance After 2020-11-17 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 9 · 2020-11-17 · Other · Acquired 67,730 · Balance 67,730

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Common StockSEC Table I · non-derivativeIndirectDirectly held by family trust controlled by Krausz11,794 Reported balance After 2020-11-17 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 10 · 2020-11-17 · Other · Acquired 11,794 · Balance 11,794

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Common StockSEC Table I · non-derivativeIndirectDirectly held by Krausz childrens trusts34,576 Reported balance After 2020-11-17 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 11 · 2020-11-17 · Other · Acquired 34,576 · Balance 34,576

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

F7: Held by affiliated trusts for the benefit of Krausz children.

Common StockSEC Table I · non-derivativeIndirectDirectly held by Krausz childrens trusts34,576 Reported balance After 2020-11-17 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 12 · 2020-11-17 · Other · Acquired 34,576 · Balance 34,576

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

F7: Held by affiliated trusts for the benefit of Krausz children.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP") and USVP X Affiliates Fund , L.P. ("AFF X" and, together with USVP X, the "USVP Funds", and may be deemed to have sole voting and dispositive power over the securities held by the USVP Funds. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

F3: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by PMG X, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

F4: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by PMG X, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.52 to $67.32, inclusive for sales on 11/18/2020. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F7: Held by affiliated trusts for the benefit of Krausz children.

ON24 INC.

Report date June 21, 2024 · Filed June 25, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect78,435 Reported balance After 2024-06-21 transaction · row 1
1 source row

Row 1 · 2024-06-21 · Grant · Acquired 30,198 · Balance 78,435

F1: Represents shares underlying restricted stock units ("RSUs"). The RSUs will vest on the earlier of (i) the date of the following year's Annual Meeting (or the date immediately prior to the next Annual Meeting if the Non-Employee Director's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the first anniversary of the date of the grant.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares underlying restricted stock units ("RSUs"). The RSUs will vest on the earlier of (i) the date of the following year's Annual Meeting (or the date immediately prior to the next Annual Meeting if the Non-Employee Director's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the first anniversary of the date of the grant.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Section 16 reporting ended · disclosed 2017-06-08. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeIndirectDirectly owned by USVP IX0 Last balance in matching sequence After 2017-06-02 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2017-06-02 · Conversion · Acquired 8,000,000 · Balance 8,000,000

F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Row 2 · 2017-06-02 · Other · Disposed 8,000,000 · Balance 0

F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

F2: Prorata distribution in kind from the partnership without consideration to its limited partners.

F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Class B Common StockSEC Table II · derivative / convertible securityIndirectDirectly owned by USVP IX3,713,775 Reported balance After 2017-06-02 transaction · row 3 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 3 · 2017-06-02 · Conversion · Disposed 8,000,000 · Balance 3,713,775

F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

F2: Prorata distribution in kind from the partnership without consideration to its limited partners.

F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

INTERMOLECULAR INC

Report date September 20, 2019 · Filed September 20, 2019

Section 16 reporting ended · disclosed 2019-09-20. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2019-09-20 transaction · row 1
1 source row

Row 1 · 2019-09-20 · Other · Disposed 538,267 · Balance 0

F1: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F2: Pursuant to the Merger Agreement, the Reporting Person disposed of all Company Shares beneficially owned by it, and received the Merger Consideration for each Company Share.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.62Direct0 Reported balance After 2019-09-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2019-09-20 · Other · Disposed 10,000 · Balance 0

F1: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.21Direct0 Reported balance After 2019-09-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2019-09-20 · Other · Disposed 10,000 · Balance 0

F1: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.59Direct0 Reported balance After 2019-09-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2019-09-20 · Other · Disposed 10,000 · Balance 0

F1: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.82Direct0 Reported balance After 2019-09-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2019-09-20 · Other · Disposed 25,000 · Balance 0

F1: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.85Direct0 Reported balance After 2019-09-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2019-09-20 · Other · Disposed 25,000 · Balance 0

F1: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.85Direct0 Reported balance After 2019-09-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2019-09-20 · Other · Disposed 25,000 · Balance 0

F1: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.39Direct0 Reported balance After 2019-09-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2019-09-20 · Other · Disposed 25,000 · Balance 0

F1: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F2: Pursuant to the Merger Agreement, the Reporting Person disposed of all Company Shares beneficially owned by it, and received the Merger Consideration for each Company Share.

F3: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

F4: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

Section 16 reporting ended · disclosed 2018-11-14. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectDirectly owned by USVP IX1,084,127 Reported balance After 2018-11-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2018-11-08 · Other · Disposed 1,084,127 · Balance 1,084,127

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect216,825 Reported balance After 2018-11-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2018-11-08 · Other · Acquired 216,825 · Balance 216,825

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-11-08 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2018-11-08 · Other · Disposed 216,825 · Balance 0

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by Irwin Federman18,212 Reported balance After 2018-11-08 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2018-11-08 · Other · Acquired 18,212 · Balance 18,212

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by Steven Krausz22,573 Reported balance After 2018-11-08 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2018-11-08 · Other · Acquired 22,573 · Balance 22,573

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by David Liddle15,391 Reported balance After 2018-11-08 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 6 · 2018-11-08 · Other · Acquired 15,391 · Balance 15,391

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by Paul Matteucci13,356 Reported balance After 2018-11-08 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 7 · 2018-11-08 · Other · Acquired 13,356 · Balance 13,356

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by Jonathan Root18,982 Reported balance After 2018-11-08 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 8 · 2018-11-08 · Other · Acquired 18,982 · Balance 18,982

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectDirectly owned by Philip Young18,212 Reported balance After 2018-11-08 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 9 · 2018-11-08 · Other · Acquired 18,212 · Balance 18,212

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Mellanox Technologies, Ltd.

Report date April 27, 2020 · Filed April 27, 2020

Section 16 reporting ended · disclosed 2020-04-27. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect0 Ending reported balance After 2020-04-27 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2020-04-27 · Disposition to issuer · Disposed 45,332 · Balance 633

F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as March 10, 2019 (the "Merger Agreement"), by and among the Issuer, NVIDIA International Holdings, Inc., a Delaware corporation ("Parent"), Teal Barvaz Ltd., a company organized under the laws of the State of Israel and a wholly owned subsidiary of Parent, and NVIDIA Corporation, a Delaware corporation in exchange for cash consideration of $125.00 per share (the "Per Share Merger Consideration"), subject to any applicable withholding taxes.

Row 2 · 2020-04-27 · Disposition to issuer · Disposed 633 · Balance 0

F2: Pursuant to the terms of the Merger Agreement, on April 27, 2020, each outstanding award of restricted stock units ("Issuer RSU") that either (i) had fully vested but had not yet settled in shares or (ii) was held by a non-employee director of the Issuer, whether vested or unvested, was cancelled in exchange for the Per Share Merger Consideration less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as March 10, 2019 (the "Merger Agreement"), by and among the Issuer, NVIDIA International Holdings, Inc., a Delaware corporation ("Parent"), Teal Barvaz Ltd., a company organized under the laws of the State of Israel and a wholly owned subsidiary of Parent, and NVIDIA Corporation, a Delaware corporation in exchange for cash consideration of $125.00 per share (the "Per Share Merger Consideration"), subject to any applicable withholding taxes.

F2: Pursuant to the terms of the Merger Agreement, on April 27, 2020, each outstanding award of restricted stock units ("Issuer RSU") that either (i) had fully vested but had not yet settled in shares or (ii) was held by a non-employee director of the Issuer, whether vested or unvested, was cancelled in exchange for the Per Share Merger Consideration less any applicable withholding taxes.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 37,268 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 5

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Federman

Disclosed balance after: 37,268

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 587,851 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 4

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by PMG X

Disclosed balance after: 0

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F4 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by PMG X, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 587,851 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 3

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by PMG X

Disclosed balance after: 587,851

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F3 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by PMG X, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 71,840 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 2

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by AFF X

Disclosed balance after: 167,627

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F2 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP") and USVP X Affiliates Fund , L.P. ("AFF X" and, together with USVP X, the "USVP Funds", and may be deemed to have sole voting and dispositive power over the securities held by the USVP Funds. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
November 17, 2020 Filed Nov 20, 2020 02:12 UTC Inari Medical, Inc. NARI · Entity 83035 OtherCommon Stock 2,245,605 Not disclosed Not disclosed
Disclosure

SEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 1

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP X

Disclosed balance after: 5,239,744

F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F2 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP") and USVP X Affiliates Fund , L.P. ("AFF X" and, together with USVP X, the "USVP Funds", and may be deemed to have sole voting and dispositive power over the securities held by the USVP Funds. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionSeries C Preferred Stock · Derivative 72,887 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 13

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by AFF X

Disclosed balance after: 0

Underlying: Common Stock · 72,887 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionSeries C Preferred Stock · Derivative 2,278,331 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 12

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP X

Disclosed balance after: 0

Underlying: Common Stock · 2,278,331 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionSeries B Preferred Stock · Derivative 92,771 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 11

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by AFF X

Disclosed balance after: 0

Underlying: Common Stock · 92,771 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionSeries B Preferred Stock · Derivative 2,899,876 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 10

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP X

Disclosed balance after: 0

Underlying: Common Stock · 2,899,876 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionSeries A Preferred Stock · Derivative 73,809 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 9

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by AFF X

Disclosed balance after: 0

Underlying: Common Stock · 73,809 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionSeries A Preferred Stock · Derivative 2,307,142 $0.00 $0.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 8

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP X

Disclosed balance after: 0

Underlying: Common Stock · 2,307,142 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 PurchaseCommon Stock 97,962 $19.00 $1,861,278.00
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · nonDerivative · entry 7

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Casey Tansey

Disclosed balance after: 97,962

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionCommon Stock 72,887 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · nonDerivative · entry 6

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by AFF X

Disclosed balance after: 239,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionCommon Stock 92,771 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · nonDerivative · entry 5

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by AFF X

Disclosed balance after: 166,580

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionCommon Stock 73,809 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · nonDerivative · entry 4

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by AFF X

Disclosed balance after: 73,809

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionCommon Stock 2,278,331 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · nonDerivative · entry 3

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP X

Disclosed balance after: 7,485,349

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionCommon Stock 2,899,876 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · nonDerivative · entry 2

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP X

Disclosed balance after: 5,207,018

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
May 27, 2020 Filed May 28, 2020 00:56 UTC Inari Medical, Inc. NARI · Entity 83035 ConversionCommon Stock 2,307,142 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-20-000010 · edgar.xml · nonDerivative · entry 1

Presidio Management Group X LLC · CIK 0001602744 · 10% owner

US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner

USVP X AFFILIATES LP · CIK 0001453359 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

Lewis Richard W. · CIK 0001534399 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP X

Disclosed balance after: 2,307,142

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein

Read SEC document
April 27, 2020 Filed Apr 27, 2020 15:44 UTC Mellanox Technologies, Ltd. MLNX · Entity 13120 Disposition to issuerOrdinary Shares 633 $125.00 $79,125.00
Disclosure

SEC source: 0001567619-20-008472 · doc1.xml · nonDerivative · entry 2

FEDERMAN IRWIN · CIK 0001192391 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: Pursuant to the terms of the Merger Agreement, on April 27, 2020, each outstanding award of restricted stock units ("Issuer RSU") that either (i) had fully vested but had not yet settled in shares or (ii) was held by a non-employee director of the Issuer, whether vested or unvested, was cancelled in exchange for the Per Share Merger Consideration less any applicable withholding taxes.

Read SEC document
April 27, 2020 Filed Apr 27, 2020 15:44 UTC Mellanox Technologies, Ltd. MLNX · Entity 13120 Disposition to issuerOrdinary Shares 45,332 $125.00 $5,666,500.00
Disclosure

SEC source: 0001567619-20-008472 · doc1.xml · nonDerivative · entry 1

FEDERMAN IRWIN · CIK 0001192391 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 633

F1 · kind: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as March 10, 2019 (the "Merger Agreement"), by and among the Issuer, NVIDIA International Holdings, Inc., a Delaware corporation ("Parent"), Teal Barvaz Ltd., a company organized under the laws of the State of Israel and a wholly owned subsidiary of Parent, and NVIDIA Corporation, a Delaware corporation in exchange for cash consideration of $125.00 per share (the "Per Share Merger Consideration"), subject to any applicable withholding taxes.

Read SEC document
September 20, 2019 Filed Sep 20, 2019 16:32 UTC INTERMOLECULAR INC IMI · Entity 154785 OtherStock Option · Derivative 25,000 Not disclosed Strike: $1.39 Not disclosed
Disclosure

SEC source: 0001567619-19-018603 · doc1.xml · derivative · entry 8

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F1 · kind: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4 · price: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3 · derivative.exercise_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

F3 · derivative.expiration_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Read SEC document
September 20, 2019 Filed Sep 20, 2019 16:32 UTC INTERMOLECULAR INC IMI · Entity 154785 OtherStock Option · Derivative 25,000 Not disclosed Strike: $0.85 Not disclosed
Disclosure

SEC source: 0001567619-19-018603 · doc1.xml · derivative · entry 7

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F1 · kind: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4 · price: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3 · derivative.exercise_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

F3 · derivative.expiration_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Read SEC document
September 20, 2019 Filed Sep 20, 2019 16:32 UTC INTERMOLECULAR INC IMI · Entity 154785 OtherStock Option · Derivative 25,000 Not disclosed Strike: $1.85 Not disclosed
Disclosure

SEC source: 0001567619-19-018603 · doc1.xml · derivative · entry 6

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F1 · kind: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4 · price: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3 · derivative.exercise_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

F3 · derivative.expiration_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Read SEC document
September 20, 2019 Filed Sep 20, 2019 16:32 UTC INTERMOLECULAR INC IMI · Entity 154785 OtherStock Option · Derivative 25,000 Not disclosed Strike: $1.82 Not disclosed
Disclosure

SEC source: 0001567619-19-018603 · doc1.xml · derivative · entry 5

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F1 · kind: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4 · price: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3 · derivative.exercise_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

F3 · derivative.expiration_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Read SEC document
September 20, 2019 Filed Sep 20, 2019 16:32 UTC INTERMOLECULAR INC IMI · Entity 154785 OtherStock Option · Derivative 10,000 Not disclosed Strike: $2.59 Not disclosed
Disclosure

SEC source: 0001567619-19-018603 · doc1.xml · derivative · entry 4

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F1 · kind: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4 · price: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3 · derivative.exercise_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

F3 · derivative.expiration_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Read SEC document
September 20, 2019 Filed Sep 20, 2019 16:32 UTC INTERMOLECULAR INC IMI · Entity 154785 OtherStock Option · Derivative 10,000 Not disclosed Strike: $8.21 Not disclosed
Disclosure

SEC source: 0001567619-19-018603 · doc1.xml · derivative · entry 3

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F1 · kind: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4 · price: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3 · derivative.exercise_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

F3 · derivative.expiration_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Read SEC document
September 20, 2019 Filed Sep 20, 2019 16:32 UTC INTERMOLECULAR INC IMI · Entity 154785 OtherStock Option · Derivative 10,000 Not disclosed Strike: $6.62 Not disclosed
Disclosure

SEC source: 0001567619-19-018603 · doc1.xml · derivative · entry 2

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F1 · kind: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F4 · price: Pursuant to the Merger Agreement, (i) each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the effective time of the merger (the "Effective Time") was accelerated, (ii) each Company Option that remained outstanding as of immediately prior to the Effective Time was canceled and terminated as of the Effective Time and (iii) the Reporting Person of such Company Option became entitled to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of company Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the per share exercise price of such Company Option.

F3 · derivative.exercise_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

F3 · derivative.expiration_date: The options are fully vested due to vesting acceleration approved by the board in connection with the Merger.

Read SEC document
September 20, 2019 Filed Sep 20, 2019 16:32 UTC INTERMOLECULAR INC IMI · Entity 154785 OtherCommon Stock 538,267 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-018603 · doc1.xml · nonDerivative · entry 1

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: On September 20, 2019, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2019, by and among EMD Group Holding II, Inc. ("Parent"), EMD Performance Materials Semiconductor Services Corp. ("Merger Sub") and Intermolecular, Inc. (the "Company"), Merger Sub merged with and into the Company, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Company Shares," and each such share, a "Company Share") (other than Canceled Company Shares and Dissenting Company Shares) was thereupon canceled and converted into the right to receive $1.20 in cash (the "Merger Consideration"), with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F2 · price: Pursuant to the Merger Agreement, the Reporting Person disposed of all Company Shares beneficially owned by it, and received the Merger Consideration for each Company Share.

Read SEC document
July 25, 2019 Filed Jul 26, 2019 18:14 UTC Mellanox Technologies, Ltd. MLNX · Entity 13120 GrantOrdinary Shares 2,532 $0.00 $0.00
Disclosure

SEC source: 0001567619-19-015253 · doc1.xml · nonDerivative · entry 1

FEDERMAN IRWIN · CIK 0001192391 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,965

F1 · shares: Restricted Share Units ("RSUs"). Upon vesting thereof, the Reporting Person is entitled to receive one (1) Ordinary Share for each one (1) RSU.

F2 · shares: The RSUs shall vest in equal monthly installments over a one year period beginning on August 1, 2019 and will be 100% vested on July 1, 2020 provided the director continues to serve as a non-employee director and provided that the RSUs shall vest in full immediately prior to a change in control.

F3 · balance_after: Includes 2,532 RSUs. Upon vesting thereof, the Reporting Person is entitled to receive one (1) Ordinary Share for each one (1) RSU.

Read SEC document
November 08, 2018 Filed Nov 14, 2018 01:13 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 OtherCommon Stock 18,212 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 9

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Philip Young

Disclosed balance after: 18,212

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
November 08, 2018 Filed Nov 14, 2018 01:13 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 OtherCommon Stock 18,982 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 8

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Jonathan Root

Disclosed balance after: 18,982

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
November 08, 2018 Filed Nov 14, 2018 01:13 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 OtherCommon Stock 13,356 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 7

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Paul Matteucci

Disclosed balance after: 13,356

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
November 08, 2018 Filed Nov 14, 2018 01:13 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 OtherCommon Stock 15,391 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 6

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by David Liddle

Disclosed balance after: 15,391

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
November 08, 2018 Filed Nov 14, 2018 01:13 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 OtherCommon Stock 22,573 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 5

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Steven Krausz

Disclosed balance after: 22,573

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
November 08, 2018 Filed Nov 14, 2018 01:13 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 OtherCommon Stock 18,212 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 4

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Irwin Federman

Disclosed balance after: 18,212

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
November 08, 2018 Filed Nov 14, 2018 01:13 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 OtherCommon Stock 216,825 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 3

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

Read SEC document
November 08, 2018 Filed Nov 14, 2018 01:13 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 OtherCommon Stock 216,825 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 2

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,825

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

Read SEC document
November 08, 2018 Filed Nov 14, 2018 01:13 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 OtherCommon Stock 1,084,127 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 1

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP IX

Disclosed balance after: 1,084,127

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
November 08, 2018 Filed Nov 13, 2018 17:17 UTC INTERMOLECULAR INC IMI · Entity 154785 OtherCommon Stock, $0.001 per share 4,280,779 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-18-000003 · edgar.xml · nonDerivative · entry 2

FEDERMAN IRWIN · CIK 0001192391 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP IX

Disclosed balance after: 0

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
November 08, 2018 Filed Nov 13, 2018 17:17 UTC INTERMOLECULAR INC IMI · Entity 154785 OtherCommon Stock, $0.001 per share 82,370 Not disclosed Not disclosed
Disclosure

SEC source: 0001548538-18-000003 · edgar.xml · nonDerivative · entry 1

FEDERMAN IRWIN · CIK 0001192391 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 538,267

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

Read SEC document
July 25, 2018 Filed Jul 27, 2018 16:36 UTC Mellanox Technologies, Ltd. MLNX · Entity 13120 GrantOrdinary Shares 4,200 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-044212 · doc4.xml · nonDerivative · entry 1

FEDERMAN IRWIN · CIK 0001192391 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,433

F1 · shares: Restricted Share Units ("RSU's"). The Reporting Person is entitled to receive one (1) ordinary share for each one (1) RSU upon vesting.

F2 · shares: The RSU's shall vest in equal monthly installments over a one year period beginning on August 1, 2018 and will be 100% vested on July 1, 2019 provided the director continues to serve as a non-employee director.

F3 · balance_after: Includes 4,200 unvested Restricted Share Units (RSU's). Upon vesting thereof, the Reporting Person is entitled to receive one (1) Ordinary Share for each one (1) RSU.

Read SEC document
May 24, 2018 Filed May 29, 2018 18:11 UTC INTERMOLECULAR INC IMI · Entity 154785 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $1.39 $0.00
Disclosure

SEC source: 0001140361-18-026080 · doc1.xml · derivative · entry 1

FEDERMAN IRWIN · CIK 0001192391 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-05-23

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier to occur of (i) the first anniversary of the date of grant and (ii) the date of the annual meeting immediately following the date of grant, subject in each case to Reporting Person's continued service through the vesting date.

Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 ConversionSeries F Convertible Preferred Stock · Derivative 3,795,620 $0.00 $0.00
Disclosure

SEC source: 0001104659-18-031866 · a4.xml · derivative · entry 12

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 570,769 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.

F1 · derivative.exercise_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.

F1 · derivative.expiration_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.

F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 ConversionSeries E Convertible Preferred Stock · Derivative 948,855 $0.00 $0.00
Disclosure

SEC source: 0001104659-18-031866 · a4.xml · derivative · entry 11

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 163,962 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date.

F3 · derivative.exercise_date: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date.

F3 · derivative.expiration_date: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date.

F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 ConversionSeries D Convertible Preferred Stock · Derivative 1,397,478 $0.00 $0.00
Disclosure

SEC source: 0001104659-18-031866 · a4.xml · derivative · entry 10

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 210,147 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.

F1 · derivative.exercise_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.

F1 · derivative.expiration_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.

F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 ConversionSeries C Convertible Preferred Stock · Derivative 3,142,670 $0.00 $0.00
Disclosure

SEC source: 0001104659-18-031866 · a4.xml · derivative · entry 9

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 472,581 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.

F1 · derivative.exercise_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.

F1 · derivative.expiration_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.

F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 ConversionSeries B Convertible Preferred Stock · Derivative 2,102,315 $0.00 $0.00
Disclosure

SEC source: 0001104659-18-031866 · a4.xml · derivative · entry 8

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 389,893 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date.

F2 · derivative.exercise_date: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date.

F2 · derivative.expiration_date: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date.

F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 ConversionSeries A Convertible Preferred Stock · Derivative 2,400,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-18-031866 · a4.xml · derivative · entry 7

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 360,902 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.

F1 · derivative.exercise_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.

F1 · derivative.expiration_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.

F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 ConversionCommon Stock 570,769 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-18-031866 · a4.xml · nonDerivative · entry 6

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,168,254

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date.

F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC Inspire Medical Systems, Inc. INSP · Entity 1186 ConversionCommon Stock 163,962 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-18-031866 · a4.xml · nonDerivative · entry 5

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,597,485

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date.

F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.